phase 2_completion
saveRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Adenocarcinoma, Colon Cancer, Colorectal Cancer
Data sources
globaldata
Found something off?
drug timeline · 8
- phase 1 completionOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)Apr 30, 2026 · 164d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalOct 29, 2025 · 347d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalOct 8, 2025 · 368d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 5, 2024 · 919d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalMar 6, 2024 · 949d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 28, 2023 · 1262d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 28, 2023 · 1262d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalNov 8, 2022 · 1433d ago
same company · ±60 days · 4
related news · 5
- biopharma diveRegeneron immunotherapy combo comes up short in melanoma trial
- oncliveCases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
- biopharma diveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
- statSTAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
- biopharma diveFDA approves Regeneron’s hearing loss gene therapy
🐶 often sniffed alongside
top 8- tagApproval60 co-mentions · 15 sources
- drugLIBTAYO60 co-mentions · 15 sources
- tagOncology12 co-mentions · 3 sources
- tagPulmonology4 co-mentions · 1 sources
- tagNSCLC3 co-mentions · 1 sources
- tagBreast Cancer3 co-mentions · 1 sources
- tagMelanoma3 co-mentions · 1 sources
- tagColorectal Cancer2 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that